Cited by 143Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryPharmacology and Nanomedicine Research

Plant-Derived Extracellular Vesicles and Their Exciting Potential as the Future of Next-Generation Drug Delivery

Open access
Alzahrani, Faisal A., Khan, Mohammad Imran, Kameli, Nader, Alsahafi, Elham, Riza, Yasir Mohamed·2023·Biomolecules

Abstract

Plant cells release tiny membranous vesicles called extracellular vesicles (EVs), which are rich in lipids, proteins, nucleic acids, and pharmacologically active compounds. These plant-derived EVs (PDEVs) are safe and easily extractable and have been shown to have therapeutic effects against inflammation, cancer, bacteria, and aging. They have shown promise in preventing or treating colitis, cancer, alcoholic liver disease, and even COVID-19. PDEVs can also be used as natural carriers for small-molecule drugs and nucleic acids through various administration routes such as oral, transdermal, or injection. The unique advantages of PDEVs make them highly competitive in clinical applications and preventive healthcare products in the future. This review covers the latest methods for isolating and characterizing PDEVs, their applications in disease prevention and treatment, and their potential as a new drug carrier, with special attention to their commercial viability and toxicological profile, as the future of nanomedicine therapeutics. This review champions the formation of a new task force specializing in PDEVs to address a global need for rigor and standardization in PDEV research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom13050839

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Plant-derived EVs offer practical advantages of lower immunogenicity and reduced risk of transmissible pathogens, greater raw-material scalability and cost-effectiveness, and easier sourcing/ethical profile compared with mammalian sources.

    “In addition, plant-derived EVs offer practical advantages of lower immunogenicity and reduced risk of transmissible pathogens, greater raw-material scalability and cost-effectiveness, and easier sourcing/ethical profile compared with mammalian sources [27].”

    From A 28-Day Pilot Study of the Effects on Facial Skin Hydration, Elasticity, and Texture of a Centella asiatica Extracellular Vesicle-Based Skin Care Formulation (2025) · cites this paper as [27]

    The Introduction (page unavailable) describes immunogenicity and ethical concerns with animal-derived EVs, and says plant EVs are easier to procure and scale up economically. It does not establish a lower risk of transmissible pathogens from plant EVs; the passages found on contamination do not make that comparison. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Alzahrani, F. A., Khan, M. I., Kameli, N., Alsahafi, E., & Riza, Y. M.
Affiliations
  • King Abdulaziz University (SA)
  • Jazan University (SA)
  • Umm al-Qura University (SA)
Corresponding author
Riza, Yasir Mohamed
Venue
Biomolecules
Publisher
MDPI AG
Published
2023-05-15
Volume
13
Issue
5
Pages
839
ISSN
2218-273X (ISSN-L)
OpenAlex
W4378516261
Cited by
143
References
99
Citations by year
2026: 57 · 2025: 43 · 2024: 36 · 2023: 7
FWCI
3.78
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
Keywords
plant-derived extracellular vesicles, drug delivery, nanomedicine, drug carriers, nucleic acid delivery, small molecule drug delivery, inflammation, cancer, colitis, alcoholic liver disease, COVID-19 pandemic, toxicology, standardization
MeSH terms
Extracellular Vesicles, COVID-19, Drug Carriers, Humans, Neoplasms, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review